» Articles » PMID: 36716311

New [1,2,4]triazolo[4,3-c]quinazolines As Intercalative Topo II Inhibitors: Design, Synthesis, Biological Evaluation, and in Silico Studies

Abstract

Fifteen quinazoline derivatives were designed and synthesized as DNA intercalators. The cytotoxicity of the designed members was assessed against HCT-116 and HepG2 cancer cell lines. In addition, the topoisomerase II (Topo II) inhibitory effect was assessed. Compound 16 was the most cytotoxic and Topo II inhibitor with low cytotoxicity against Vero cells. Compounds 16, 17, and 18 showed significant DNA binding affinities. Compound 16 showed Topo II catalytic inhibitory effect at a concentration of 10 μM. Further mechanistic investigations revealed the capability of compound 16 to induce apoptosis in HCT-116 cells and arrest the growth at the S and G2/M phases. Also, compound 16 showed a significant increase in the level of BAX (2.18-fold) and a marked decrease in the level of Bcl-2 (1.9-fold) compared to the control cells. In silico studies revealed the ability of the synthesized members to bind to the DNA-Topo II complex.

Citing Articles

New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies.

Mohamed A, Alshammari M, Aly A, Sadek K, Ahmad A, Aziz E J Enzyme Inhib Med Chem. 2024; 39(1):2311818.

PMID: 38488131 PMC: 10946275. DOI: 10.1080/14756366.2024.2311818.


Synthesis, DFT calculations, and anti-proliferative evaluation of pyrimidine and selenadiazolopyrimidine derivatives as dual Topoisomerase II and HSP90 inhibitors.

El-Kalyoubi S, El-Sebaey S, Rashad A, Al-Ghulikah H, Ghorab M, Elfeky S J Enzyme Inhib Med Chem. 2023; 38(1):2198163.

PMID: 37036011 PMC: 10088926. DOI: 10.1080/14756366.2023.2198163.

References
1.
Lee J, Cheng X, Swails J, Yeom M, Eastman P, Lemkul J . CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J Chem Theory Comput. 2015; 12(1):405-13. PMC: 4712441. DOI: 10.1021/acs.jctc.5b00935. View

2.
Nitiss J . Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009; 9(5):338-50. PMC: 2748742. DOI: 10.1038/nrc2607. View

3.
Miller 3rd B, McGee Jr T, Swails J, Homeyer N, Gohlke H, Roitberg A . MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J Chem Theory Comput. 2015; 8(9):3314-21. DOI: 10.1021/ct300418h. View

4.
Zhou D, Lu Y, Mai Y, Zhang C, Xia J, Yao P . Design, synthesis and biological evaluation of novel perimidine o-quinone derivatives as non-intercalative topoisomerase II catalytic inhibitors. Bioorg Chem. 2019; 91:103131. DOI: 10.1016/j.bioorg.2019.103131. View

5.
Liu L . DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989; 58:351-75. DOI: 10.1146/annurev.bi.58.070189.002031. View